>
Switch to:

Cellectar Biosciences Shiller PE Ratio

: (As of Today)
View and export this data going back to 2005. Start your Free Trial

Shiller PE for Stocks: The True Measure of Stock Valuation


Cellectar Biosciences Shiller PE Ratio Historical Data

The historical data trend for Cellectar Biosciences's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cellectar Biosciences Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Shiller PE Ratio
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Cellectar Biosciences Quarterly Data
Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21
Shiller PE Ratio Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison

For the Biotechnology subindustry, Cellectar Biosciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Cellectar Biosciences Shiller PE Ratio Distribution

For the Biotechnology industry and Healthcare sector, Cellectar Biosciences's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Cellectar Biosciences's Shiller PE Ratio falls into.



Cellectar Biosciences Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Cellectar Biosciences's E10 for the quarter that ended in Sep. 2021 is calculated as:

For example, Cellectar Biosciences's adjusted earnings per share data for the three months ended in Sep. 2021 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Sep. 2021 (Change)*Current CPI (Sep. 2021)
=-0.1/115.7343*115.7343
=-0.100

Current CPI (Sep. 2021) = 115.7343.

Cellectar Biosciences Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201112 -120.000 95.213 -145.863
201203 -120.000 96.783 -143.498
201206 -120.000 96.819 -143.444
201209 -120.000 97.633 -142.248
201212 -100.000 96.871 -119.472
201303 -140.000 98.209 -164.982
201306 -72.000 98.518 -84.582
201309 -46.000 98.790 -53.890
201312 -139.000 98.326 -163.610
201403 -103.000 99.695 -119.572
201406 -73.000 100.560 -84.016
201409 6.000 100.428 6.914
201412 -44.255 99.070 -51.699
201503 -30.400 99.621 -35.317
201506 -30.200 100.684 -34.714
201509 -24.600 100.392 -28.360
201512 15.000 99.792 17.396
201603 9.100 100.470 10.483
201606 -4.900 101.688 -5.577
201609 -4.300 101.861 -4.886
201612 -5.560 101.863 -6.317
201703 -2.400 102.862 -2.700
201706 -2.320 103.349 -2.598
201709 -2.580 104.136 -2.867
201712 -3.400 104.011 -3.783
201803 -2.070 105.290 -2.275
201806 -1.690 106.317 -1.840
201809 -1.650 106.507 -1.793
201812 -0.809 105.998 -0.883
201903 -0.760 107.251 -0.820
201906 -0.460 108.070 -0.493
201909 -0.420 108.329 -0.449
201912 -0.330 108.420 -0.352
202003 -0.420 108.902 -0.446
202006 -0.260 108.767 -0.277
202009 -0.150 109.815 -0.158
202012 -0.070 109.897 -0.074
202103 -0.130 111.754 -0.135
202106 -0.110 114.631 -0.111
202109 -0.100 115.734 -0.100

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Cellectar Biosciences  (NAS:CLRB) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Cellectar Biosciences Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Cellectar Biosciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Cellectar Biosciences Business Description

Cellectar Biosciences logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
100 Campus Drive, Florham Park, NJ, USA, 07932
Cellectar Biosciences Inc is a clinical stage biopharmaceutical company. It focusses on development of targeted phospholipid drug conjugates for the treatment and imaging of cancer. The company's pipeline consists of pre-clinical and clinical product candidates including radiotherapeutic and chemotherapeutic phospholipid drug conjugates. Its portfolio of products in development includes CLR 131, CTX Product Portfolio consisting of CTX CLR 1800-P, CTX CLR 1602-PTX and CTX CLR 1700, CLR 125, CLR 124, and CLR 1502.
Executives
Friend John E. Ii officer: VP, Chief Medical Officer 26 ORCHARD LANE COLT NECK NJ 07722
Swirsky Douglas J director C/O REXAHN PHARMACEUTICALS, INC. 15245 SHADY GROVE ROAD SUITE 455 ROCKVILLE MD 20850
Neis John director 505 S. ROSA ROAD, SUITE 201 MADISON WI 53719
Hill Stephen A director 50 AVENUE GENERAL DE GAULLE BRUXELLES C9 9999999999
Driscoll Frederick W director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: DRISCOLL FREDERICK W a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Loren Stefan director 3226 AVENIDA DE SUENO CARLSBAD CA 92009
Elefant Dov officer: Chief Financial Officer EPICEPT CORPORATION 270 SYLVAN AVENUE ENGLEWOOD CLIFFS NJ 07632
Caruso James V director, officer: President and CEO C/O CELLECTAR BIOSCIENCES, INC. 8383 GREENWAY BLVD STE 600 MIDDLETON WI 53562
Longcor Jarrod officer: Chief Business Officer C/O RIB-X PHARMACEUTICALS, INC. 300 GEORGE STREET, SUITE 301 NEW HAVEN CT 06511
Grachev Igor D officer: Chief Medical Officer 15 REID LANE MILLSTONE TWP NJ 08535
Bernhardt Charles Thomas Iii officer: Interim CFO 23 BIRCH ROAD MALVERN PA 19355
Posner Brian M officer: Chief Financial Officer 1590 REED ROAD PENNINGTON NJ 08534
Hamill John P. officer: Interim CFO 4092 NEW HOPE ROAD FURLONG PA 18925
Kolean Chad J officer: VP, Chief Financial Officer C/O CELLECTAR BIOSCIENCES, INC. 3301 AGRICULTURE DRIVE MADISON WI 53716
Hertzberg Richard other: significant owner 1329 STRATFORD COURT DEL MAR CA 92014

Cellectar Biosciences Headlines

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)